LivaNova PLC Announces the First Patient Enrolled in the PERSIST-AVR Trial
LONDON, 2016-04-04 15:00 CEST (GLOBE NEWSWIRE) -- LivaNova, PLC (NASDAQ:LIVN) (LSE:LIVN) (the “Company”), a global medical technology company, announced today the first implant of the Perceval sutureless valve in the PERSIST-AVR (Perceval Sutureless Implant Vs Standard Aortic Valve Replacement) trial at CHU Brabois, University of Lorraine, Nancy, France. Engineered to restore the natural valve performance, Perceval is a sutureless heart valve for patients who require replacement of their aortic valve.
PERSIST-AVR is the first worldwide, prospective, randomized, multi-center trial, comparing Perceval sutureless aortic valve with standard sutured bioprostheses in patients with aortic valve disease. The study will enroll over 1,200 patients with severe symptomatic aortic stenosis or steno-insufficiency in patients who are candidates for surgical replacement of their native aortic valve. The primary endpoint of the trial is non-inferiority of Major Adverse Cardiac Cerebrovascular Events (MACCE) at one year according to VARC-2 criteria.1
“The clinical experience with the Perceval valve has been positive on multiple fronts as measured by reduced cross-clamp time, great hemodynamic performance, low structural valve deterioration and freedom from reoperation up to five-year follow-up.2 PERSIST-AVR is designed to confirm these results compared to standard sutured stented valves. Moreover, the trial will demonstrate how the use of Perceval in aortic valve surgery is linked with significant cost savings, driven primarily by reduced procedural costs and reduced hospital stay,” said Professor Thierry Folliguet, M.D., Ph.D., who enrolled the first patient in PERSIST-AVR. Prof. Folliguet is part of the Steering Committee of the study and one of the early implanters of Perceval.
Conducted worldwide, the study is planned to have a two-year enrollment period and a yearly follow-up for a five-year period. The primary endpoint is expected to be available in 2019.
“We know that PERSIST-AVR is a landmark clinical trial, being the first randomized study in 30 years in the field of valvular surgery. Its initiation is a great endeavor in the cardiac surgery communities. More than 60 centers around the world will be recruited pointing out the strong interest generated by Perceval. We look forward to obtaining promising data for the use of Perceval in the daily aortic valve replacement setting,” said Professor Theodor Fischlein, M.D., Ph.D., Paracelsus Medical University Cardiovascular Center, Nuremberg, Germany, and Dr. Roberto Lorusso, M.D., Ph.D., Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands, both principal investigators of the study.
“As the first trial of its kind, the PERSIST-AVR study is a significant milestone for LivaNova, the healthcare community and patients worldwide,” said Michel Darnaud, President, Cardiac Surgery B.U., LivaNova, PLC. “We are proud to support this important trial. We anticipate its results could significantly impact daily practice and establish the Perceval sutureless valve as the prosthesis of choice for future heart valve surgeries.”
To date, the Perceval sutureless valve has been implanted in more than 15,000 patients in over 310 hospitals worldwide. More than 115 publications testify the good clinical results obtained with the device. The Perceval valve is approved for use in Europe, US and other international markets including Canada and Australia.
1 Kappetein, A. P., Head S. J., Genereux P., et al. “Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation: The Valve Academic Research Consortium-2 Consensus Document." J Thorac Cardiovasc Surg 145, no. 1 (2013): 6-23.
2 Shrestha M. , Fischlein T., Meuris B. et al. “European multicentre experience with the sutureless Perceval valve: clinical and haemodynamic outcomes up to 5 years in over 700 patients” Eur J Cardiothorac Surg. 2016 Jan;49(1):234-41
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.
Safe harbor statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words. Statements contained in this press release are based on information presently available to LivaNova and assumptions that the parties believe to be reasonable. LivaNova is not assuming any duty to update this information if those facts change or if the assumptions are no longer believed to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning developing novel opportunities in heart failure, sleep apnea and percutaneous mitral valve, creating new innovative solutions that benefit patients, healthcare professionals, and healthcare systems, and building significant shareholder value. Important factors that may cause actual results to differ include, but are not limited to: risks that the new businesses will not be integrated successfully or that the combined companies will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer to realize than expected; the inability of LivaNova to meet expectations regarding the timing, completion and accounting and tax treatments; risks relating to unanticipated costs of integration, including operating costs, customer loss or business disruption being greater than expected; reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services; unanticipated changes relating to competitive factors in the industries in which the company operates; the ability to hire and retain key personnel; the ability to attract new customers and retain existing customers in the manner anticipated; reliance on and integration of information technology systems; changes in legislation or governmental regulations affecting the company; international, national or local economic, social or political conditions that could adversely affect the company or its customers; conditions in the credit markets; risks to the industries in which LivaNova operates that are described in the "Risk Factors" section of the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC by Cyberonics, Inc. and LivaNova and the analogous section in annual reports and other documents filed from time to time by Sorin S.p.A. with the Italian financial market regulator (CONSOB); risks associated with assumptions made in connection with critical accounting estimates and legal proceedings; LivaNova’s' international operations, which are subject to the risks of currency fluctuations and foreign exchange controls; and the potential of international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the parties' businesses, including those described in Cyberonics' Annual Report on Form 10-K, as amended from time to time, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the SEC by Cyberonics and LivaNova and those described in Sorin's annual reports, registration documents and other documents filed from time to time with CONSOB by Sorin. LivaNova does not give any assurance (1) that LivaNova will achieve its expectations, or (2) concerning any result or the timing thereof, in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results.
For more information, please visit www.livanova.com, or contact:
Investor Relations and Media
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Equis and Global Infrastructure Partners Announce Closing of US$5.0 Billion Renewable Energy Generation Acquisition of Equis Energy19.1.2018 17:28 | Pressemelding
Singapore, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Equis Pte. Ltd (Equis) and Global Infrastructure Partners (GIP) announcedtoday the closing of the previously announced sale by Equis of 100% of the equity interest in Equis Energyto GIP and its co-investors, for an enterprise value of USD5.0 billion (including assumed liabilities of USD1.3bn). The net transaction consideration has been settled in cash. Headquartered in Singapore, Equis Energy is the largest renewable energy independent power producer(IPP) in the Asia-Pacific region (APAC), with more than 180 assets comprising 11,135MW in operation,construction and development across APAC including Australia, Japan, India, Indonesia, the Philippinesand Thailand. The transaction is the largest renewable energy generation acquisition in history and positions GIP as adominant renewable energy developer in the key OECD growth markets of Australia and Japan, as well asacross India and South-East Asia. About Equis Energy Equis Energy operates from
XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa19.1.2018 14:00 | Pressemelding
Open Label Extension Results, which Demonstrate Significant Improvements in HS Patients Previously Treated with Placebo, will be Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) AUSTIN, Texas, Jan. 19, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that results from an open label extension (OLE) phase of the randomized Phase 2 study evaluating XBiotech's True Human(TM) antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS), will be presented at the European Hidradenitis Suppurativa Foundation (EHSF) Conference occurring in Rotterdam Netherlands February 7-9th. The oral presentation titled, "An open-label extension study of MABp1 targeting interleukin-1alpha for hidradenitis suppurativa (HS)" will be given by Theodora Kanni, M.D., Ph.D., Attikon University Hospital in Athens Greece, on 8 February 2018 between 1:50 and 2:50pm local time. The findings being presented come from patients that had received placebo in
The Search for #AconfidentYou Role Models Kicks Off at the Xehar Fashion Fairies Conference19.1.2018 12:00 | Pressemelding
Expanding their Fashion Fairies Program, Xehar Teaches and Inspires Women Through Confidence EL SEGUNDO, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Today, the Xehar team announces the Xehar Fashion Fairies Conference, which takes place over three days in Los Angeles, January 19th-21st. The conference gathers aspiring fashionistas to celebrate self love, natural beauty, and learn what it takes inspire women to be more confident. With powerful keynotes, exciting breakout sessions, a fashion show and international networking opportunities, the conference is a unique blend that is new to the fashion industry. "We are searching for our 2018 Fashion Fairies who are serious about a career in fashion and want to inspire women worldwide," says Hadari Oshri, founder and CEO of Xehar. "Attendees will learn how to become one of our exclusive #AconfidentYou Fashion Fairies." Propelled by the successful launch of its existing influencer outreach, Xehar has now expanded their Fashion Fairies program t
Olympus Labs Partners with Leading Korean Fintech Company Metaps Plus19.1.2018 00:03 | Pressemelding
Gibraltar, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Olympus Labs is quickly becoming an emerging global leader in the cryptocurrency-based financial product space, and on the heels of a successful token sale, Olympus is partnering with Seoul-based corporation Metaps Plus, a leading Korean fintech company and mobile marketing platform developer. This news comes shortly after the company announced OKEx, as its official exchange for the company's token MOT. "This is an amazing partnership for us, as it will allow us to hit the Korean market in a big way. We will be able to tap directly into the tens of millions of users on the Metaps Plus platform, allowing users to access financial products created by Olympus," said Kai Chen, CEO of Olympus Labs. "This is a key milestone as it demonstrates that Olympus products can be integrated in third party platforms such as mobile apps, wallets, exchanges, and even physical atms and pos systems, allowing users throughout the world access to Olympus products
Forward Industries Acquires Intelligent Product Solutions18.1.2018 23:54 | Pressemelding
WEST PALM BEACH, Fla. and HAUPPAUGE, N.Y., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Forward Industries (NASDAQ:FORD) today announced the acquisition of Intelligent Product Solutions (IPS), an industry leading product design and development company based in Long Island, New York for a material consideration comprising of cash, equity, and contingent earn outs. IPS clients include leading brands in consumer electronics, medical devices, enterprise and security solution providers and Internet of Things connected solutions, including Google, Physio Control, PepsiCo, Motorola, ABInBev, Zebra and Charity Water. Commenting on the transaction, Terry Wise, CEO of Forward Industries remarked, "I am delighted and excited with the acquisition of IPS. The company is an excellent strategic fit for Forward Industries. Its expertise and strong track record in designing connected/IOT products and developing products such as the AdhereTech 'smart' pill bottle will significantly strengthen and contribute to For
VITEC to Highlight EZ TV IPTV and Digital Signage Platform in First ISE Appearance18.1.2018 21:06 | Pressemelding
PARIS, Jan. 18, 2018 (GLOBE NEWSWIRE) -- In its first-ever attendance at Integrated Systems Europe (ISE), VITEC, a worldwide leader in advanced video encoding and streaming solutions, will showcase EZ TV - a market-leading, broadcast-grade IPTV and digital signage platform with key installations in Europe and the U.S. Targeted to enterprises, sports stadiums and arenas, and government agencies, EZ TV combines low-latency, broadcast-quality IPTV distribution with powerful digital signage capabilities to give audiences a more engaging and interactive experience. "As Europe's largest show for AV systems integrators, ISE is the perfect forum for us to present our EZ TV IPTV platform," said Bruno Teissier, sales and marketing director, VITEC. "We're looking forward to showing ISE attendees how they can help their customers distribute broadcast-quality IPTV content and access powerful digital signage capabilities in an all-in-one, integrated solution." Designed to integrate seamlessly with a
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom